Venous Stenting Eased Post-Thrombotic Syndrome In Trial

At six months, investigators report that venous stenting was associated with less post-thrombotic severity than standard treatment alone in patients after deep vein thrombosis. The NIH-sponsored, multi-site C-TRACT trial randomly assigned patients with post-thrombotic syndrome to stent placement plus standard treatment or to standard treatment alone. Over the first six months of follow-up, researchers observed better symptom measures and a lower burden of severe disease in the stent group. The study compared two care strategies for persistent venous disability after clot treatment and tested whether reopening the blocked vein was associated with less post-thrombotic burden.

The study enrolled 225 patients across 29 U.S. sites after at least three months of treatment for deep vein thrombosis. Participants had iliac vein blockage involving a major pelvic vein, and the obstruction was associated with substantial disability. Enrollment therefore centered on patients with persistent limitations rather than mild residual symptoms. At study entry, 93% met clinical criteria for severe post-thrombotic syndrome, defining a cohort with pronounced symptoms before randomized treatment began.

The procedure used a stent, described as a mesh tube placed into the vein through tiny incisions during a two-to-three-hour operation. In the intervention arm, the device was added to the usual components of standard treatment. The comparison approach relied on compression and blood-thinning medications without stent placement. Investigators framed the strategies as supportive care with or without a mechanical intervention to reopen the vein.

At six months, 40% of the stent group still had severe post-thrombotic syndrome, compared with 61% of the standard-care group. Researchers also reported better leg symptoms among patients who underwent stent placement than among those who received standard treatment alone. The pattern was consistent across clinician-assessed severity and patient-reported leg manifestations within the same follow-up window.

The investigators also noted a patient-reported advantage on a 100-point quality-of-life scale, where the stent group scored 14 points higher than standard treatment alone. That difference reflected better overall functioning and well-being from the patient perspective at the same assessment. The quality-of-life result added a distinct patient-centered outcome alongside the reported differences in post-thrombotic burden.

Key Takeaways

• A multi-site randomized trial compared venous stenting plus standard treatment with standard treatment alone in patients with post-thrombotic syndrome after deep vein thrombosis.
• Enrolled patients had iliac vein blockage, substantial disability, and high baseline severity at study entry.
• At six months, lower severe post-thrombotic syndrome rates, better leg symptoms, and higher quality-of-life scores were reported in the stent group.